𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term durability of response to adalimumab in Crohn's disease

✍ Scribed by M. Chaparro; J. Panés; V. García; O. Merino; P. Nos; E. Domènech; M. Peñalva; E. García-Planella; M. Esteve; J. Hinojosa; M. Andreu; F. Muñoz; A. Gutiérrez; J.L. Mendoza; J. Barrio; M. Barreiro-de; I. Vera; P. Vilar; J.L. Cabriada; M.A. Montoro; X. Aldeguer; C. Saro; J.P. Gisbert

Book ID
112101145
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
819 KB
Volume
18
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dosage adjustment during long-term adali
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics
✍ William J. Sandborn; Jean-Frédéric Colombel; Stefan Schreiber; Scott E. Plevy; P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB 👁 2 views

Background: Data from CHARM, a 56-week, randomized controlled trial of adalimumab for patients with moderately to severely active Crohn's disease (CD), were used to evaluate outcomes of adalimumab dosage adjustment. Methods: Patients randomized to blinded adalimumab 40 mg every other week (EOW) in

The long-term outcome in Crohn's disease
The long-term outcome in Crohn's disease
✍ P. H. Harper; V. W. Fazio; I. C. Lavery; D. G. Jagelman; F. L. Weakley; R. G. Fa 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 528 KB